Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012
Trends in osteoporosis treatment with oral and intravenous bisphosphonates in the United States, 2002-2012
复制标题
DOI：
10.1016/j.bone.2013.09.008
复制
发表时间：
2013-12-01
期刊：
影响因子：
4.1
通讯作者：
Greene, Patty
中科院分区：
文献类型：
--
作者：
Wysowski, Diane K.;Greene, Patty
双膦酸盐已被广泛用于绝经后妇女治疗和预防骨质疏松症。鉴于最近的安全性问题报告的背景，关于最佳使用时间的问题，以及福善美专利于2008年2月到期，我们访问了药品营销研究数据库的数据，以描述口服双膦酸盐的处方和销售趋势，患者和处方者的特征，2002年，美国零售药店开出的口服双膦酸盐处方估计有2130万张，增长了46%。2007年和2008年达到3100万的峰值，2012年下降了53%，为1470万。销售数据（在所有护理环境中销售的包装数量）显示出平行趋势（从2002年到2007年增长66%，从2007年到2012年下降51%）。同样，用于治疗骨质疏松症的静脉注射双膦酸盐销售量从2007年的14.95万包增长到2010年的56.16万包，增长了3.8倍，随后在2012年下降了22%。来自正在进行的每月办公室调查的数据表明，医生主要在因骨质疏松症而就诊的较低体重的老年白人女性中提到口服双膦酸盐。2002年至2012年期间，亚洲人访视和骨质疏松诊断中提及口服双膦酸盐的频率增加。这些数据表明，在美国，用于骨质疏松症治疗的口服（自2007-2008年以来）和静脉注射（自2010年以来）双膦酸盐的处方和销售量大幅下降。未来的研究应考虑下降的原因和影响。爱思唯尔公司出版
Bisphosphonates have been widely prescribed to postmenopausal women for treatment and prevention of osteoporosis. Given a background of reports of recent safety problems, questions about optimal duration of use, and the patent expiration of Fosamax in February 2008, we accessed data from pharmaceutical marketing research databases to describe trends in dispensed prescriptions and sales of oral bisphosphonates, characteristics of patients and prescribers, and sales of intravenous bisphosphonates for osteoporosis treatment.An estimated 21.3 million prescriptions for oral bisphosphonates were dispensed in U.S. retail pharmacies in 2002 that increased 46% to a peak of 31.0 million in 2007 and 2008, and declined by 53% in a four year-period to 14.7 million in 2012. Sales data (number of packages sold in all settings of care) showed parallel trends (66% increase from 2002 through 2007 and 51% decrease from 2007 through 2012). Similarly, intravenous bisphosphonate sales for osteoporosis treatment grew 3.8-fold from 149.5 thousand packages in 2007 to 561.6 thousand in 2010, followed by a 22% decrease in 2012.Data from an ongoing monthly office-based survey indicated physicians mentioned oral bisphosphonates primarily in visits of older aged Caucasian women with lower body mass for osteoporosis. Frequencies of oral bisphosphonate mentions increased between 2002 and 2012 in visits of Asians and for osteopenia diagnoses. These data indicate a substantial decline in prescriptions and sales of oral (since 2007-2008) and intravenous (since 2010) bisphosphonates for osteoporosis treatment in the United States. Reasons for, and implications of, the decline should be considered for future research. Published by Elsevier Inc.